Once again, a record-setting revenue year for OTC.

ORSERDU approved by the FDA

A new breast cancer therapeutic developed at Duke has received FDA approval and is going to the market.

Isolere Bio acquired by Donaldson

A Duke professor and graduate student built the company around their phase-separating purification technology.

Tellus Therapeutics raises a $35M Series A round

Neonatal care company commercializing breast milk-based therapies based on Duke research is thriving.


This year, we helped launch a variety of start-ups with offerings from smart toilets to 4D mammography.

$1M+ awarded through Gilhuly Accelerator Fund

OTC’s new translational fund has been deployed to support 14 Duke research projects with commercial potential.

November 28th, 2023
5th Annual Invented at Duke Celebration

Duke’s Office for Translation & Commercialization invites you to Invented at Duke 2023, the annual celebration and showcase of Duke inventors and inventions. It will be held 4:30-7PM at the Penn Pavilion on Duke campus.

This event will feature inventors with booths, resource tables, drinks and hors d’oeuvres, gifts for Duke inventors who register and attend, as well as brief remarks from President Price and OTC head Robin Rasor. The featured speaker this year is the Schiciano Family Distinguished Professor of Electrical and Computer Engineering Jungsang Kim, co-founder of quantum start-up IonQ. We hope to see you there!



The pipeline for commercialization begins here.

Triangle Venture Day gathers steam

Duke New Ventures and counterparts at UNC, NC State, and the NC Biotech Center are growing this regular event into a Southeastern VC staple.

Faculty donates back to OTC

Professor Jungsang Kim and his wife Soyeon Nam gave $1M to OTC to help fellow entrepreneurial Duke inventors.

Translation & Commercialization as a collaborative, creative process

OTC licensing managers are creative partners to Duke inventors – just ask pathologist Dr. Soman Abraham and OTC’s Dr. Dennis Thomas.

Four Points Innovation funds its first project

Therapeutics development partnership with investment firm Deerfield Management is sprouting commitments.